Linezolid
Linezolid

Linezolid

Restricted

Low
Excellent (90 to 100%)
IV: $19.05/dose PO: $1.77/dose

Spectrum of Activity

Dosing

General Information

  • CBC
  • Visual testing for therapy >3 months or if symptoms develop on therapy
  • LFTs
  • Lactic acid in patients with renal dysfunction
  • Serotonin syndrome
  • Thrombocytopenia
  • Rash
  • Elevated liver enzymes
  • Lactic acidosis
  • Myelosuppression (usually with >2weeks therapy; reversible)
  • Peripheral/optic neuropathy with prolonged courses
  • Absorption: Rapid and extensive
  • Distribution: 0.65 L/kg
  • Protein binding: Adults: 31%
  • Metabolism: Hepatic via oxidation of the morpholine ring, resulting in two inactive metabolites (aminoethoxyacetic acid, hydroxyethyl glycine); minimally metabolized, may be mediated by cytochrome P450
  • Bioavailability: Oral: ~100%.
  • Half-life elimination: 4.9 hours
  • Time to peak: Oral: 1 to 2 hours
  • Excretion: Urine (~30% of total dose as parent drug, ~50% of total dose as metabolites); two metabolites of linezolid may accumulate in patients with severe renal impairment; feces (~9% of total dose as metabolites)